Professor Ioanna Gouni-Berthold, University of Cologne, Germany, discusses recently published and ongoing studies of antisense oligonucleotides, small interfering RNAs and small molecules targeting Lp(a).
As Lp(a) Forum celebrates its first year since launch, Dr Elias Björnson, University of Gothenburg, Sweden, picks some memorable scientific advances and clinical developments in the field of Lp(a) research during the past 12 months and looks forward to further investigations that will translate these findings into real world practice.
Professor Keith Ferdinand, Tulane University School of Medicine, New Orleans, USA, explains the importance of Lp(a) testing at least once in a patient’s life.
Professor Marc Dweck, University of Edinburgh, UK, reports recent imaging research that links Lp(a) to progression of the most unstable coronary plaques.
Professor Florian Kronenberg, Medical University of Innsbruck, Austria, shows how the genetics of Lp(a) is informing links with cardiovascular outcomes.
More than 1 billion people worldwide are likely to have elevated Lp(a) but levels vary with ethnicity and gender. Professor Pia Kamstrup, Copenhagen University Hospital, Denmark discusses the evidence and its implications for cardiovascular risk in different populations.
(Founding Partner)
Novartis has provided with arm’s length sponsorship towards the set-up of the Lp(a) Forum. The content was developed independently by the Forum.